Cancidas

Selected form

Caspofungin

Treatment option: Aspergillosis,Aspergilloma, Fungal Infection, Infection, Candidiasis,Vaginal

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cancidas

What is Cancidas?

Cancidas is an antifungal medication that belongs to a class of drugs known as echinocandins. It is designed to treat various types of fungal infections by interfering with the production of a specific component of the fungal cell wall called glucan. Without enough glucan, the fungal cell wall becomes weak and unstable, which helps the body's immune system clear the infection.

Primary Uses

This medication is typically used in a hospital setting for individuals who have serious fungal infections. Its primary applications include:

Candidiasis: Treating infections caused by Candida, a type of yeast that can affect the bloodstream, abdomen, or the lining of the esophagus.
Aspergillosis: Treating infections caused by Aspergillus, a common mold. This is often reserved for cases where other antifungal treatments have not been effective or cannot be tolerated by the patient.
Empiric Therapy: Treating suspected fungal infections in patients who have a high fever and a low white blood cell count (neutropenia), which often occurs during cancer treatments or after organ transplants.

How it Works

Unlike some other antifungal medications that target the cell membrane, Cancidas specifically inhibits the enzyme 1,3-beta-D-glucan synthase. Because human cells do not possess this enzyme or a cell wall structure similar to fungi, the medication is designed to target the fungal cells specifically while minimizing impact on human cells.

What side effects are possible with Cancidas?

Adverse Reaction Scope

Category	Description
Key Adverse Reaction Categories	Includes General/Constitutional effects (e.g., Pyrexia, Chills), Gastrointestinal effects (e.g., Diarrhea, Nausea), Hematologic changes (e.g., Anemia), and Infusion-related reactions (e.g., Flushing, Infusion site pain).
Frequency Classification	Very Common (ge 10%): Reactions documented in official sources include Pyrexia (fever), Headache, Diarrhea, and increases in liver enzyme tests (ALT/AST increased). Common (ge 1% to < 10%): Includes Nausea, Abdominal pain, Phlebitis/Thrombophlebitis, Anemia, and Hypokalemia (decreased blood potassium).
System-Organ Classes Involved	Reactions are classified by physiological systems, including Hepatobiliary Disorders, Immune System Disorders, Vascular Disorders, Gastrointestinal Disorders, and Investigations (Laboratory abnormalities).
Serious Adverse Reactions	Officially documented serious events include Anaphylaxis (a severe hypersensitivity reaction) and rare post-marketing reports of severe cutaneous reactions such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). Isolated cases of Hepatic Failure have also been reported.
Population-Specific Safety Considerations	Hepatic Impairment: Increased drug exposure is observed; a reduced daily dose is required for adult patients with moderate hepatic impairment. Pediatric Patients: The frequency profile of very common reactions differs, specifically including Hypotension and Rash.
Safety-Related Restrictions or Limitations	Discontinuation is officially mandated at the first signs or symptoms of a potential hypersensitivity reaction (e.g., severe rash, facial swelling). The label also notes that patients who develop abnormal liver function tests should be monitored for evidence of worsening hepatic function.

Safety Classifications (High-Level)

Classification Detail	Regulatory Statement
Regulatory Frequency Framework Used	The safety data utilizes formal frequency bands (e.g., Very Common, Common, Uncommon) consistent with regulatory standards for drug labeling.
Regulatory Basis	All safety information is based on the official prescribing information approved by government health authorities, such as the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA).
Context-of-Use Safety Notes	Co-administration with Cyclosporine has been associated with transient elevated liver enzymes (ALT and AST), a documented safety consequence that necessitates close monitoring of liver enzymes.

Resulting Safety Structure

Regulatory Safety Summary:

The official label classifies the most frequent adverse reactions as Very Common, which include Pyrexia and changes in liver enzyme levels documented under Investigations.
Serious adverse events, such as Anaphylaxis and severe dermatological reactions, are explicitly highlighted in the official prescribing information.
Safety is stratified by population, specifically addressing differences for pediatric patients and monitoring requirements for those with hepatic impairment.

Connection to the overall safety profile: The official safety profile structures the understanding of risks by providing a neutral, categorized inventory of possible adverse reactions and known serious events. This regulatory framework separates effects by their observed frequency and the physiological system they affect, allowing users to differentiate between common clinical findings and rare but critical safety restrictions. The inclusion of specific population and monitoring notes formally defines the known boundaries of the medicine's systemic safety characteristics.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents regarding Caspofungin acetate (Cancidas) overdose focus primarily on the required emergency actions and supportive management rather than a specific set of unique acute symptoms. This approach is based on clinical trial data showing that doses significantly higher than the standard regimen, specifically up to 210 mg per day administered over a period of up to 49 days, did not result in unexpected or dose-limiting toxicity in adults.

Immediate Action Required

In all cases of suspected overdose, immediate medical attention must be sought. Official guidance mandates that the management approach must be symptomatic and supportive to address any clinical manifestations that may arise.

Management Constraints

Overdose management is constrained by two critical factors stated in the official prescribing information: No specific antidote is known for the medication, and the drug is not dialyzable. This means that the drug cannot be effectively removed from the body through procedures like hemodialysis due to its high protein binding.

Risk and Monitoring

While unique overdose symptoms are not documented, the potential for known severe adverse reactions, such as hepatic dysfunction or anaphylaxis (a serious allergic reaction), remains a concern during excessive systemic exposure. Patients with moderate hepatic impairment are noted to have a higher risk of increased systemic exposure, which requires special clinical consideration in an overdose scenario. Clinical monitoring and observation are required for continuous patient support.

Therapeutic Uses of Cancidas

Caspofungin (Cancidas) is indicated for addressing several severe fungal disease states. The medication is generally applied in clinical settings that involve acute or unstable symptom patterns, contributing to easing the overall symptom load.

The primary therapeutic domain is the management of conditions presenting with systemic or localized discomfort, such as Invasive Candidiasis (including bloodstream and deep-seated infections), Invasive Aspergillosis in high-risk patients, and Esophageal Candidiasis. Cancidas may assist with the clearance of the pathogenic fungus, which supports improved day-to-day comfort during symptomatic periods.

It is commonly used across conditions presenting with acute episodes where patients are severely immunocompromised (e.g., febrile neutropenia) or as salvage therapy when other antifungals have not responded or are poorly tolerated. This provides supportive relief when symptoms interfere with routine activities.

“This use is applied in addressing the fungal presence and is relevant for easing the symptoms of discomfort, pain, or difficulty when swallowing associated with fungal growth in the esophagus.”

Quick Fact: Relief for Systemic Discomfort
Cancidas is primarily used to address symptoms related to systemic imbalance and heightened physiological activity associated with the presence of invasive fungi, supporting a more stable condition during acute episodes.

Regulatory References

EMA therapeutic overview

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Cancidas

Regulatory documentation strictly defines which populations are eligible for Caspofungin (Cancidas).

Category	Eligibility Status as Defined in Regulatory Label	Classification
Absolute Exclusion	Known hypersensitivity to Caspofungin acetate or any product excipient.	Contraindicated
Age Group (Established Use)	Adults and Pediatric Patients who are 3 months of age and older.	Allowed
Age Group (Use Not Established)	Infants/Neonates who are younger than 3 months of age.	Use Not Established
Hepatic Function	Moderate Hepatic Impairment (Child-Pugh score 7–9) in adults.	Conditional Use
Renal Function	All degrees of Renal Impairment (kidney function).	Unrestricted
Pregnancy/Lactation	Use during pregnancy and breastfeeding.	Not Recommended

The official eligibility profile is structured around the sole absolute restriction, which is a history of hypersensitivity. Age-related approval allows for use starting at three months, with use in younger infants remaining not established by regulators. While Caspofungin is unrestricted based on kidney function, the status of adult patients with moderate hepatic impairment is classified as conditional use and requires special monitoring according to the official label.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory documents for Caspofungin (Cancidas) detail specific interactions that primarily affect the plasma concentration of the medicine or co-administered drugs. The only formal contraindication listed is a known hypersensitivity to any component of the formulation.

Exposure-Altering Interactions

Co-administration with Cyclosporine results in an officially documented increase in Caspofungin plasma exposure (AUC) by approximately 35%. This outcome is linked to Cyclosporine inhibiting the uptake transport of Caspofungin into the liver. The co-use of these two agents requires monitoring for transient increases in liver enzymes, as noted in the regulatory labels. Conversely, Caspofungin reduces the trough concentration of Tacrolimus by 26%, which mandates monitoring and dosage adjustment for Tacrolimus.

Interactions Affecting Clearance

Medicines categorized as inducers of hepatic drug clearance may lead to clinically meaningful reductions in Caspofungin concentrations. These interacting agents include Rifampin, Nevirapine, Efavirenz, Carbamazepine, Dexamethasone, and Phenytoin. An adjustment to the Caspofungin dose may be required when any of these inducers are co-administered.

Administration and Population Constraints

Caspofungin is subject to strict procedural constraints: the product must not be mixed or co-infused with other intravenous medications, and solutions containing dextrose (alpha-D-glucose) are prohibited for preparation. The interaction profile also notes that patients with moderate hepatic impairment exhibit increased Caspofungin exposure due to naturally slower clearance, necessitating a population-specific consideration.

Mechanism of Action

Specific Inhibition of Fungal Cell Wall Synthesis

Cancidas (caspofungin) acts by non-competitive inhibition of the fungal enzyme beta-(1,3)-D-glucan synthase (GCS), targeting the Fks1 subunit. This interaction is highly selective, as this enzyme and its product are absent in mammalian cells.

Molecular Cascade and Selective Pathogen Lysis

Inhibition of GCS prevents the formation of beta-(1,3)-D-glucan, a crucial structural polysaccharide required for the integrity and osmotic stability of the fungal cell wall. This molecular deficit leads to the loss of structural support, causing the fungal cell to become osmotically unstable. The resulting cascade is rapid, culminating in cell lysis and death (fungicidal action) against actively growing susceptible fungi. This mechanism produces the elimination of the target cell population without primarily modulating host physiological functions.

Dosage and Administration Information

Cancidas (Caspofungin acetate) is exclusively administered via intravenous (IV) infusion and is never administered as a rapid injection or taken orally. The administration method requires the lyophilized powder to undergo a two-step process of reconstitution and subsequent dilution into an approved solution, specifically forbidding the use of diluents containing dextrose (glucose). The medicine must be infused slowly over a period of approximately 60 minutes and cannot be co-administered or mixed with other medications in the same IV line.

Dosing Schedule and Duration

The standard protocol involves a two-phase daily dosing schedule. Treatment generally starts with a single 70 mg loading dose on Day 1, followed by a 50 mg maintenance dose once daily beginning on Day 2. For specific clinical situations, such as inadequate response or co-administration with certain enzyme-inducing medicines, the maintenance dose may be escalated to 70 mg daily. Dosage recommendations for children aged three months and older are calculated based on body surface area (BSA), following the same loading and maintenance structure, but with a maximum daily dose of 70 mg.

Population-Specific Use

Instructions require a dose reduction for adults with moderate hepatic impairment (Child-Pugh 7 to 9), lowering the maintenance dose to 35 mg daily, though the 70 mg loading dose is still typically given. Conversely, no dosage adjustment is required for any degree of renal impairment. The treatment for confirmed invasive fungal infections often continues for a minimum of 14 days or for a defined period after symptom resolution.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Cancidas

Research was conducted on Caspofungin (Cancidas) for several serious fungal conditions. The body of evidence consists primarily of regulatory studies, including Randomized Controlled Trials (RCTs) that evaluate Caspofungin against other established regimens, along with open-label studies and analyses focusing on specific patient groups. This summary outlines the structures of these studies, what they measured, and where scientific uncertainty remains, without offering any clinical advice.

Evidence for use in Invasive Candidiasis (Including Candidemia)

Research regarding Invasive Candidiasis was primarily conducted through RCTs. These studies were designed to explore patterns related to the medicine's use in adults, children over 12 months of age, and geriatric patients. The main research focus was on outcomes related to microbiological clearance (research exploring the fungal clearance endpoint) and the attainment of a Favorable Overall Response. Data show patterns related to recorded Day 30 all-cause mortality in these observed populations. Long-term effects are not fully established, and research exploring contexts like CNS infections remains limited.

Evidence for use in Empirical Therapy for Presumed Fungal Infections

Research exploring this approach was primarily conducted in comparative clinical trials focusing on patients with a fever who are neutropenic (low white blood cell count). The studies tracked a complex five-part composite endpoint to assess various measures, including the absence of new infections and survival over defined time intervals. The evidence base is focused on this specific population, and limited generalizability exists. Furthermore, because treatment is based on suspicion, the studies include many patients whose infections are not later confirmed as fungal, which limits the certainty of the findings.

Evidence in Special Patient Populations

Studies have explored the use of Caspofungin across different age groups. Paediatric populations and children/adolescents were evaluated in dedicated or subgroup analyses. Research also examined specific adult subgroups, such as older adults and those with moderate hepatic (liver) impairment. These studies monitored physiological markers related to liver function. Data for other groups, such as those with severe kidney issues or women who are pregnant, remain insufficient in clinical trials.

Frequently Asked Questions (FAQ)

Common questions about Cancidas (FAQ)

Q: How long does a typical course of treatment with Cancidas last?

According to official regulatory documents, the typical duration of treatment for confirmed invasive infections is often a minimum of 14 days. Treatment duration is also guided by factors such as the time needed for fungal cultures to become negative and for clinical signs and symptoms to improve.

Q: What are the most common side effects patients experience with Cancidas?

Official product information, derived from clinical trials, shows that very common side effects (those affecting 10% or more of patients) include pyrexia (fever), headache, and diarrhea. Increases in certain liver enzyme tests (ALT/AST) are also frequently reported, as noted in the adverse reaction frequency data.

Q: Can Cancidas cause a skin rash or other types of allergic reactions?

Yes, official safety information indicates that hypersensitivity reactions have been reported with Cancidas. These reactions can include rash, flushing, and facial swelling. If symptoms of a severe hypersensitivity reaction, like anaphylaxis, are observed, the medication must be discontinued.

Q: Can Cancidas be used in children and infants?

Cancidas is approved for use in pediatric patients who are three months of age and older. However, official regulatory documents indicate that use in infants younger than three months of age has not been studied or formally established.

Q: Are there any known long-term side effects after stopping Cancidas treatment?

Regulatory clinical trials primarily evaluate the drug's safety and effectiveness over a defined period of treatment. The official product information indicates that long-term effects beyond the period of initial clinical trials are generally not well-established in the regulatory data.

Q: Is it possible for the fungus to become resistant to Cancidas over time?

Official microbiology information acknowledges that, similar to other antifungals, the potential for drug resistance to develop in fungal pathogens exists. This is based on in vitro (laboratory) findings, although clinical data on this topic can be limited.

Q: Why is Cancidas not recommended for use during pregnancy or while breastfeeding?

For pregnancy, official product information, based on animal studies, indicates that there is a potential risk of fetal harm. For breastfeeding, use is not recommended because official product information states it is unknown if the drug is excreted into human milk.

Q: What should a patient look out for as a potential sign of liver trouble?

Official patient counseling information describes symptoms that may be potential signs of liver trouble. These include nausea, vomiting, loss of appetite, pain or tenderness in the upper stomach, dark urine, or yellow skin or eyes.

Q: What are the common but less severe side effects, like headache or diarrhea?

Official product information also lists common reactions (affecting 1% to 10% of patients) that are generally less severe. These include nausea, abdominal pain, phlebitis (vein inflammation), anemia (low red blood cell count), and hypokalemia (decreased blood potassium).

Q: Is liver monitoring required while a patient is on Cancidas?

Official warnings state that patients who develop abnormal liver function tests should be monitored closely to check for worsening liver function. Furthermore, official labeling states that liver enzyme monitoring is necessary when Cancidas is co-administered with the medicine Cyclosporine.

Q: What is 'empirical therapy' when talking about Cancidas use?

In regulatory terms, empirical therapy is the approach of starting treatment for a suspected fungal infection before it is officially confirmed. This is typically done in patients who have a fever and neutropenia (a low white blood cell count).

Q: How is the dose of Cancidas determined for a child?

For children aged three months and older, the dose is determined based on the patient's body surface area (BSA). This method is used to calculate the appropriate amount of medication for children, up to a 70 mg maximum daily dose.

Q: Why might a patient experience pain or irritation at the IV injection site?

Pain or irritation at the injection site are known adverse reactions reported in clinical trials. The official safety data lists conditions like phlebitis and thrombophlebitis, which involve inflammation and potential clotting at the vein site where the medication is infused.

Q: Are there different forms or strengths of the Cancidas vial?

Cancidas is supplied as a lyophilized (freeze-dried) powder for solution for infusion. According to official product labeling, it is available in two different single-dose vial strengths: 50 mg and 70 mg.

Q: Are there any studies comparing the effectiveness of Cancidas in adults versus children?

Official clinical evidence includes dedicated studies or subgroup analyses conducted in both adult and pediatric populations. These studies allow regulators to evaluate and compare the efficacy endpoints and safety profiles across both age groups.

Q: Why must Cancidas be prepared with a specific liquid diluent?

Cancidas must be prepared using specific liquid diluents because official instructions strictly forbid mixing it with any solution containing dextrose (glucose). This is because the drug is chemically not stable in such solutions.

Q: Does Cancidas have any effect on bacterial or viral infections?

The mechanism of action for Cancidas is highly specific to fungi, as it only targets the beta-(1,3)-D-glucan component of the fungal cell wall. Therefore, its clinical use is restricted to fungal infections and it does not have indications for treating bacterial or viral infections.

Q: Does Cancidas affect or require monitoring of electrolytes like potassium and magnesium?

Official safety data indicates that Cancidas can affect electrolyte levels. Hypokalemia, which is a decrease in blood potassium, is listed as a commonly reported adverse reaction in patients receiving the medication.

Q: What are the clinical signs that indicate Cancidas treatment is working?

Treatment success, as measured in clinical studies, is characterized by the microbiological clearance of the fungus and an improvement in clinical signs, such as the resolution of fever. This is referred to as achieving a 'favorable overall response'.

Q: Is it normal to feel flu-like symptoms after receiving a Cancidas infusion?

While the official label does not use the term 'flu-like symptoms,' it does list pyrexia (fever) and chills as common to very common adverse reactions. These are general effects often associated with the body's response during or after an infusion.

Q: Is there a maximum daily dose of Cancidas that should not be exceeded?

Official dosing guidelines state that for pediatric patients, the daily dose should not exceed 70 mg. The standard adult maintenance dose can be adjusted up to 70 mg daily for specific clinical situations.

Q: Why are some of the reported side effects related to blood cell counts?

Adverse reactions for Cancidas are officially categorized by the physiological systems they affect. These categories include Hematologic disorders, which cover changes in blood cell counts, such as the reported occurrences of anemia (low red blood cell count).

Q: Can Cancidas be used for localized fungal infections like thrush?

Official regulatory indications for Cancidas include the treatment of esophageal candidiasis, which is a specific type of localized fungal infection of the esophagus.

How should Cancidas be stored and disposed of?

How to Store and Dispose of Cancidas?

The storage of Cancidas (caspofungin acetate) is strictly defined to maintain its integrity, with requirements specified for the unopened vial and the prepared solution.

Storage Requirements

Product State	Temperature Range	Conditions
Unopened Vial	2 C to 8 C (36 F to 46 F)	Store refrigerated, do not freeze, protect from light and moisture.
Reconstituted Solution	le 25 C (77 F)	Stable for a maximum of 24 hours.
Final Infusion Solution	2 C to 8 C	Stable for a maximum of 48 hours.

Storage must always be in the original container, and the product must be kept out of the sight and reach of children.

Disposal Instructions

Any unused portion of the medication must be discarded. Disposal of the unused product and all related waste materials must be carried out in accordance with local requirements for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.